159 related articles for article (PubMed ID: 32117773)
1. DNA-PK Inhibitor, M3814, as a New Combination Partner of Mylotarg in the Treatment of Acute Myeloid Leukemia.
Carr MI; Zimmermann A; Chiu LY; Zenke FT; Blaukat A; Vassilev LT
Front Oncol; 2020; 10():127. PubMed ID: 32117773
[TBL] [Abstract][Full Text] [Related]
2. DNA-PK inhibitor peposertib enhances p53-dependent cytotoxicity of DNA double-strand break inducing therapy in acute leukemia.
Haines E; Nishida Y; Carr MI; Montoya RH; Ostermann LB; Zhang W; Zenke FT; Blaukat A; Andreeff M; Vassilev LT
Sci Rep; 2021 Jun; 11(1):12148. PubMed ID: 34108527
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models.
Zenke FT; Zimmermann A; Sirrenberg C; Dahmen H; Kirkin V; Pehl U; Grombacher T; Wilm C; Fuchss T; Amendt C; Vassilev LT; Blaukat A
Mol Cancer Ther; 2020 May; 19(5):1091-1101. PubMed ID: 32220971
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Implications of p53 Status on Cancer Cell Fate Following Exposure to Ionizing Radiation and the DNA-PK Inhibitor M3814.
Sun Q; Guo Y; Liu X; Czauderna F; Carr MI; Zenke FT; Blaukat A; Vassilev LT
Mol Cancer Res; 2019 Dec; 17(12):2457-2468. PubMed ID: 31551253
[TBL] [Abstract][Full Text] [Related]
5. DNA-PK inhibition by M3814 enhances chemosensitivity in non-small cell lung cancer.
Wang M; Chen S; Wei Y; Wei X
Acta Pharm Sin B; 2021 Dec; 11(12):3935-3949. PubMed ID: 35024317
[TBL] [Abstract][Full Text] [Related]
6. AZD-7648, a DNA-PK Inhibitor, Induces DNA Damage, Apoptosis, and Cell Cycle Arrest in Chronic and Acute Myeloid Leukemia Cells.
Lapa BS; Costa MI; Figueiredo D; Jorge J; Alves R; Monteiro AR; Serambeque B; Laranjo M; Botelho MF; Carreira IM; Sarmento-Ribeiro AB; Gonçalves AC
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895013
[TBL] [Abstract][Full Text] [Related]
7. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia.
Hamann PR; Hinman LM; Hollander I; Beyer CF; Lindh D; Holcomb R; Hallett W; Tsou HR; Upeslacis J; Shochat D; Mountain A; Flowers DA; Bernstein I
Bioconjug Chem; 2002; 13(1):47-58. PubMed ID: 11792178
[TBL] [Abstract][Full Text] [Related]
8. Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models.
Wise HC; Iyer GV; Moore K; Temkin SM; Gordon S; Aghajanian C; Grisham RN
Sci Rep; 2019 Dec; 9(1):18882. PubMed ID: 31827119
[TBL] [Abstract][Full Text] [Related]
9. An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker.
Hamann PR; Hinman LM; Beyer CF; Lindh D; Upeslacis J; Flowers DA; Bernstein I
Bioconjug Chem; 2002; 13(1):40-6. PubMed ID: 11792177
[TBL] [Abstract][Full Text] [Related]
10. An Anti-CLL-1 Antibody-Drug Conjugate for the Treatment of Acute Myeloid Leukemia.
Zheng B; Yu SF; Del Rosario G; Leong SR; Lee GY; Vij R; Chiu C; Liang WC; Wu Y; Chalouni C; Sadowsky J; Clark V; Hendricks A; Poon KA; Chu W; Pillow T; Schutten MM; Flygare J; Polson AG
Clin Cancer Res; 2019 Feb; 25(4):1358-1368. PubMed ID: 29959143
[TBL] [Abstract][Full Text] [Related]
11. Pre-clinical activity of the oral DNA-PK inhibitor, peposertib (M3814), combined with radiation in xenograft models of cervical cancer.
Gordhandas SB; Manning-Geist B; Henson C; Iyer G; Gardner GJ; Sonoda Y; Moore KN; Aghajanian C; Chui MH; Grisham RN
Sci Rep; 2022 Jan; 12(1):974. PubMed ID: 35046420
[TBL] [Abstract][Full Text] [Related]
12. FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia.
Norsworthy KJ; Ko CW; Lee JE; Liu J; John CS; Przepiorka D; Farrell AT; Pazdur R
Oncologist; 2018 Sep; 23(9):1103-1108. PubMed ID: 29650683
[TBL] [Abstract][Full Text] [Related]
13. A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability.
ten Cate B; Bremer E; de Bruyn M; Bijma T; Samplonius D; Schwemmlein M; Huls G; Fey G; Helfrich W
Leukemia; 2009 Aug; 23(8):1389-97. PubMed ID: 19262596
[TBL] [Abstract][Full Text] [Related]
14. The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells.
ten Cate B; Samplonius DF; Bijma T; de Leij LF; Helfrich W; Bremer E
Leukemia; 2007 Feb; 21(2):248-52. PubMed ID: 17122863
[TBL] [Abstract][Full Text] [Related]
15. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
[TBL] [Abstract][Full Text] [Related]
16. The cytotoxic effects of gemtuzumab ozogamicin (mylotarg) in combination with conventional antileukemic agents by isobologram analysis in vitro.
Tanaka M; Kano Y; Akutsu M; Tsunoda S; Izumi T; Yazawa Y; Miyawaki S; Mano H; Furukawa Y
Anticancer Res; 2009 Nov; 29(11):4589-96. PubMed ID: 20032408
[TBL] [Abstract][Full Text] [Related]
17. Inhibiting DNA-PKcs in a non-homologous end-joining pathway in response to DNA double-strand breaks.
Dong J; Zhang T; Ren Y; Wang Z; Ling CC; He F; Li GC; Wang C; Wen B
Oncotarget; 2017 Apr; 8(14):22662-22673. PubMed ID: 28186989
[TBL] [Abstract][Full Text] [Related]
18. Nursing implications of mylotarg: a novel antibody-targeted chemotherapy for CD33+ acute myeloid leukemia in first relapse.
Shannon-Dorcy K
Oncol Nurs Forum; 2002 May; 29(4):E52-9. PubMed ID: 12011919
[TBL] [Abstract][Full Text] [Related]
19. Gemtuzumab ozogamicin in acute myeloid leukemia.
Godwin CD; Gale RP; Walter RB
Leukemia; 2017 Sep; 31(9):1855-1868. PubMed ID: 28607471
[TBL] [Abstract][Full Text] [Related]
20. DNA-PK Inhibitor Peposertib Amplifies Radiation-Induced Inflammatory Micronucleation and Enhances TGFβ/PD-L1 Targeted Cancer Immunotherapy.
Carr MI; Chiu LY; Guo Y; Xu C; Lazorchak AS; Yu H; Qin G; Qi J; Marelli B; Lan Y; Sun Q; Czauderna F; Zenke FT; Blaukat A; Vassilev LT
Mol Cancer Res; 2022 Apr; 20(4):568-582. PubMed ID: 34980594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
